Sebaceous lesions and their associated syndromes: Part II

Journal of the American Academy of Dermatology

Volumn 61, Issue 4, 2009, Pages 563-578

  Eisen, Daniel B ^a   Michael, Daniel J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kaiser Permanente ^*  (United States)

Author keywords

DNA mismatch repair; epidermal nevus syndrome; linear nevus sebaceous syndrome; Lynch syndrome; microsatellite instability; MLH 1; MSH 2; MSH 6; Muir Torre syndrome; nevus sebaceous of Jadassohn; PMS 2

Indexed keywords

ALGORITHM; CANCER SCREENING; COLON TUMOR; COLONOSCOPY; DIAGNOSTIC PROCEDURE; DUODENOSCOPY; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MENTAL DEFICIENCY; METHYLATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUIR TORRE SYNDROME; NEVUS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SEBACEOUS GLAND DISEASE; SEIZURE; SKIN TUMOR;

DERMATOLOGY; EDUCATION, MEDICAL, CONTINUING; HUMANS; SEBACEOUS GLAND DISEASES; SEBACEOUS GLAND NEOPLASMS;

EID: 69949136196     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.04.059     Document Type: Review

References (162)

1. Warnke P.H., Hauschild A., Schimmelpenning G.W., Terheyden H., Sherry E., and Springer I.N. The sebaceous nevus as part of the Schimmelpenning-Feuerstein-Mims Syndrome-an obvious phacomatosis first documented in 1927. J Cutan Pathol 30 (2003) 470-472
2. Schimmelpenning G.W. Clinical contribution to symptomatology of phacomatosis. [in German]. Fortschr Geb Rontgenstr Nuklearmed 87 (1957) 716-720
3. Menascu S., and Donner E.J. Linear nevus sebaceous syndrome: case reports and review of the literature. Pediatr Neurol 38 (2008) 207-210
4. Solomon L.M., and Esterly N.B. Epidermal and other congenital organoid nevi. Curr Probl Pediatr 6 (1975) 1-56
5. Herbst B.A., and Cohen M.E. Linea nevus sebaceus. A neurocutaneous syndrome associated with infantile spasms. Arch Neurol 24 (1971) 317-322
6. Alper J., Holmes L.B., and Mihm Jr. M.C. Birthmarks with serious medical significance: nevocullular nevi, sebaceous nevi, and multiple café au lait spots. J Pediatr 95 (1979) 696-700
7. Alper J.C., and Holmes L.B. The incidence and significance of birthmarks in a cohort of 4,641 newborns. Pediatr Dermatol 1 (1983) 58-68
8. Sugarman J.L. Epidermal nevus syndromes. Semin Cutan Med Surg 26 (2007) 221-230
9. Bianchine J.W. The nevus sebaceous of Jadassohn. A neurocutaneous syndrome and a potentially premalignant lesion. Am J Dis Child 120 (1970) 223-228
10. Happle R. Cutaneous manifestation of lethal genes. Hum Genet 72 (1986) 280
11. Levin S., Robinson R.O., Aicardi J., and Hoare R.D. Computed tomography appearances in the linear sebaceous naevus syndrome. Neuroradiology 26 (1984) 469-472
12. Carlson J.A., Cribier B., Nuovo G., and Rohwedder A. Epidermodysplasia verruciformis-associated and genital-mucosal high-risk human papillomavirus DNA are prevalent in nevus sebaceus of Jadassohn. J Am Acad Dermatol 59 (2008) 279-294
13. Rogers M., McCrossin I., and Commens C. Epidermal nevi and the epidermal nevus syndrome. A review of 131 cases. J Am Acad Dermatol 20 (1989) 476-488
14. Rogers M. Epidermal nevi (2000), Blackwell, London
15. van de Warrenburg B.P., van Gulik S., Renier W.O., Lammens M., and Doelman J.C. The linear naevus sebaceus syndrome. Clin Neurol Neurosurg 100 (1998) 126-132
16. Marden P.M., and Venters Jr. H.D. A new neurocutaneous syndrome. Am J Dis Child 112 (1966) 79-81
17. Lansky L.L., Funderburk S., Cuppage F.E., Schimke R.N., and Diehl A.M. Linear sebaceous nevus syndrome. A hamartoma variant. Am J Dis Child 123 (1972) 587-590
18. Oranje A.P., Przyrembel H., Meradji M., Loonen M.C., and de Klerk J.B. Solomon's epidermal nevus syndrome (type: linear nevus sebaceus) and hypophosphatemic vitamin D-resistant rickets. Arch Dermatol 130 (1994) 1167-1171
19. Andriola M. Nevus unius lateralis and brain tumor. Am J Dis Child 130 (1976) 1259-1261
20. Sugarman G.I., and Reed W.B. Two unusual neurocutaneous disorders with facial cutaneous signs. Arch Neurol 21 (1969) 242-247
21. Clancy R.R., Kurtz M.B., Baker D., Sladky J.T., Honig P.J., and Younkin D.P. Neurologic manifestations of the organoid nevus syndrome. Arch Neurol 42 (1985) 236-240
22. Moynahan E.J., and Wolff O.H. A new neurocutaneous syndrome (skin, eye, brain) consisting of linear nevus, bilateral lipodermoids of the conjunctiva, cranial thickening, cerebral cortical atrophy, and mental retardation. Br J Dermatol 79 (1967) 651-652
23. Pavone L., Curatolo P., Rizzo R., Micali G., Incorpora G., Garg B.P., et al. Epidermal nevus syndrome: a neurologic variant with hemimegalencephaly, gyral malformation, mental retardation, seizures, and facial hemihypertrophy. Neurology 41 (1991) 266-271
24. Lovejoy Jr. F.H., and Boyle Jr. W.E. Linear nevus sebaceous syndrome: report of two cases and a review of the literature. Pediatrics 52 (1973) 382-387
25. Lantis S., Leyden J., Thew M., and Heaton C. Nevus sebaceus of Jadassohn. Part of a new neurocutaneous syndrome?. Arch Dermatol 98 (1968) 117-123
26. Shochot Y., Romano A., Barishak Y.R., Feinstein A., Brish M., Birnbaum E., et al. Eye findings in the linear sebaceous nevus syndrome: a possible clue to the pathogenesis. J Craniofac Genet Dev Biol 2 (1982) 289-294
27. Katz B., Wiley C.A., and Lee V.W. Optic nerve hypoplasia and the syndrome of nevus sebaceous of Jadassohn. A new association. Ophthalmology 94 (1987) 1570-1576
28. Kurokawa T., Sasaki K., Hanai T., Goya N., and Komaki S. Linear nevus sebaceus syndrome. Report of a case with Lennox-Gastaut syndrome following infantile spasms. Arch Neurol 38 (1981) 375-377
29. Besser F.S. Linear sebaceous naevi with convulsions and mental retardation (Feuerstein-Mims' syndrome), vitamin-D-resistant rickets. Proc R Soc Med 69 (1976) 518-520
30. Kalis B., Degos R., Harmel L., and Roset-Charles J. Verrucoid sebaceous nevus with neurological, ocular and osseous manifestations (Solomon's nevus). [in French]. Ann Dermatol Syphiligr (Paris) 100 (1973) 380-381
31. Lall K. Teratoma of conjunctiva. Acta Ophthalmol (Copenh) 40 (1962) 555-558
32. Mollica F., Pavone L., and Nuciforo G. Linear sebaceous nevus syndrome in a newborn. Am J Dis Child 128 (1974) 868-871
33. Berg J.M., and Crome L. A possible case of atypical tuberous sclerosis. J Ment Defic Res 4 (1960) 24-31
34. Gorduren S. Aberrant lacrimal gland associated with other congenital abnormalities. Br J Ophthalmol 46 (1962) 277-280
35. Baker R.S., Ross P.A., and Baumann R.J. Neurologic complications of the epidermal nevus syndrome. Arch Neurol 44 (1987) 227-232
36. Tripp J.H., Joseph M.C., and Reay H.A. A new neurocutaneous syndrome (skin, eye, brain and heart syndrome). Proc R Soc Med 64 (1971) 23-24
37. Haslam R.H., and Wirtschafter J.D. Unilateral external oculomotor nerve palsy and nevus sebaceous of Jadassohn. Arch Ophthalmol 87 (1972) 293-300
38. Monahan R.H., Hill C.W., and Venters H.D. Multiple choristomas, convulsions and mental retardation as a new neurocutaneous syndrome. Am J Ophthalmol 64 suppl (1967) 529-532
39. Moorjani R., and Shaw D.G. Feuerstein and Mims syndrome with resistant rickets. Pediatr Radiol 5 (1976) 120-122
40. Zaremba J., Wislawski J., Bidzinski J., Kansy J., and Sidor B. Jadassohn's naevus phakomatosis: I. A report of two cases. J Ment Defic Res 22 (1978) 91-102
41. Meythaler H. Ocular findings in syndroma of Schimmelpenning-Feuerstein and Mims. [author's transl]. Klin Monatsbl Augenheilkd 166 (1975) 244-246
42. Solomon L.M., Fretzin D.F., and Dewald R.L. The epidermal nevus syndrome. Arch Dermatol 97 (1968) 273-285
43. Holden K.R., and Dekaban A.S. Neurological involvement in nevus unis lateris and nevus linearis sebaceus. Neurology 22 (1972) 879-887
44. Wilkes S.R., Campbell R.J., and Waller R.R. Ocular malformation in association with ipsilateral facial nevus of Jadassohn. Am J Ophthalmol 92 (1981) 344-352
45. el-Shanti H., Bell W.E., and Waziri M.H. Epidermal nevus syndrome: subgroup with neuronal migration defects. J Child Neurol 7 (1992) 29-34
46. Meyerson L.B. Nevus unius lateralis, brain tumor, and diencephalic syndrome. Arch Dermatol 95 (1967) 501-504
47. Pack G.T., and Sunderland D.A. Nevus unius lateris. Arch Surg 43 (1941) 341-375
48. Berkeley W.T. Nevus sebaceus (Jadassohn) complicated by bilateral salivary gland adenocarcinoma. Plast Reconstr Surg Transplant Bull 23 (1959) 55-63
49. Sakkas N., Schramm A., Gellrich N.C., Gutwald R., Duker J., and Schmelzeisen R. The ameloblastic fibroodontoma of the maxilla: case report of a child with Schimmelpenning-Feuerstein-Mims syndrome/skin-eye-brain-heart syndrome. J Oral Maxillofac Surg 64 (2006) 524-527
50. Torre D. Multiple sebaceous tumors. Arch Dermatol 98 (1968) 549-551
51. Muir E.G., Bell A.J., and Barlow K.A. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg 54 (1967) 191-195
52. Schwartz R.A., and Torre D.P. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 33 (1995) 90-104
53. Lynch H.T., Fusaro R.M., Roberts L., Voorhees G.J., and Lynch J.F. Muir-Torre syndrome in several members of a family with a variant of the Cancer Family Syndrome. Br J Dermatol 113 (1985) 295-301
54. Bitran J., and Pellettiere E.V. Multiple sebaceous gland tumors and internal carcinoma: Torre's syndrome. Cancer 33 (1974) 835-836
55. Bakker P.M. Tjon A Joe SS. Multiple sebaceous gland tumours, with multiple tumours of internal organs. A new syndrome?. Dermatologica 142 (1971) 50-57
56. Cohen P.R., Kohn S.R., and Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med 90 (1991) 606-613
57. Rothenberg J., Lambert W.C., Vail Jr. J.T., Nemlick A.S., and Schwartz R.A. The Muir-Torre (Torre's) syndrome: the significance of a solitary sebaceous tumor. J Am Acad Dermatol 23 (1990) 638-640
58. Schwartz R.A., Goldberg D.J., Mahmood F., DeJager R.L., Lambert W.C., Najem A.Z., et al. The Muir-Torre syndrome: a disease of sebaceous and colonic neoplasms. Dermatologica 178 (1989) 23-28
59. Schwartz R.A., Flieger D.N., and Saied N.K. The Torre syndrome with gastrointestinal polyposis. Arch Dermatol 116 (1980) 312-314
60. Barana D., van der Klift H., Wijnen J., Longa E.D., Radice P., Cetto G.L., et al. Spectrum of genetic alterations in Muir-Torre syndrome is the same as in HNPCC. Am J Med Genet A 125 (2004) 318-319
61. Ollila S., Fitzpatrick R., Sarantaus L., Kariola R., Ambus I., Velsher L., et al. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC. Int J Oncol 28 (2006) 149-153
62. Kruse R., Rutten A., Lamberti C., Hosseiny-Malayeri H.R., Wang Y., Ruelfs C., et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 63 (1998) 63-70
63. South C.D., Hampel H., Comeras I., Westman J.A., Frankel W.L., and de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 100 (2008) 277-281
64. Boland C.R. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 4 (2005) 211-218
65. Lynch H.T., Smyrk T., and Lynch J.F. Molecular genetics and clinical-pathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Oncology 55 (1998) 103-108
66. Lynch H.T., Lynch P.M., Pester J., and Fusaro R.M. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med 141 (1981) 607-611
67. Lynch H.T., Smyrk T.C., Watson P., Lanspa S.J., Lynch J.F., Lynch P.M., et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104 (1993) 1535-1549
68. Lynch H.T., Watson P., Smyrk T.C., Lanspa S.J., Boman B.M., Boland C.R., et al. Colon cancer genetics. Cancer 70 (1992) 1300-1312
69. Lynch H.T., Lynch P.M., Albano W.A., and Lynch J.F. The cancer family syndrome: a status report. Dis Colon Rectum 24 (1981) 311-322
70. Byfield S.A., and Syngal S. Clinical guidelines versus universal molecular testing: are we ready to choose an optimal strategy for Lynch syndrome identification?. Am J Gastroenterol 103 (2008) 2837-2840
71. Hirai Y., Banno K., Suzuki M., Ichikawa Y., Udagawa Y., Sugano K., et al. Molecular epidemiological and mutational analysis of DNA mismatch repair (MMR) genes in endometrial cancer patients with HNPCC-associated familial predisposition to cancer. Cancer Sci 99 (2008) 1715-1719
72. Genuardi M., Anti M., Capozzi E., Leonardi F., Fornasarig M., Novella E., et al. MLH1 and MSH2 constitutional mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer. Int J Cancer 75 (1998) 835-839
73. Felton K.E., Gilchrist D.M., and Andrew S.E. Constitutive deficiency in DNA mismatch repair: is it time for Lynch III?. Clin Genet 71 (2007) 499-500
74. Vasen H.F., Watson P., Mecklin J.P., and Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116 (1999) 1453-1456
75. Akiyama Y., Sato H., Yamada T., Nagasaki H., Tsuchiya A., Abe R., et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 57 (1997) 3920-3923
76. Miyaki M., Konishi M., Tanaka K., Kikuchi-Yanoshita R., Muraoka M., Yasuno M., et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 17 (1997) 271-272
77. Peltomaki P., and Vasen H.F. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 113 (1997) 1146-1158
78. Doxey B.W., and Kuwada S.K. Hereditary nonpolyposis colon cancer: revised Bethesda criteria, immunohistocheisty, microsatellite instability, germline analysis, and emerging issues in genetic testing. Curr Colorectal Cancer Rep (2007) 3
79. Jiricny J. Mediating mismatch repair. Nat Genet 24 (2000) 6-8
80. Fishel R., Lescoe M.K., Rao M.R., Copeland N.G., Jenkins N.A., Garber J., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 77 (1994) 167
81. Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., Lescoe M.K., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368 (1994) 258-261
82. Lawes D.A., SenGupta S., and Boulos P.B. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol 29 (2003) 201-212
83. Kruse R., and Ruzicka T. DNA mismatch repair and the significance of a sebaceous skin tumor for visceral cancer prevention. Trends Mol Med 10 (2004) 136-141
84. Mangold E., Rahner N., Friedrichs N., Buettner R., Pagenstecher C., Aretz S., et al. MSH6 mutation in Muir-Torre syndrome: could this be a rare finding?. Br J Dermatol 156 (2007) 158-162
85. Chhibber V., Dresser K., and Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol 21 (2008) 159-164
86. Jones B., Oh C., Mangold E., and Egan C.A. Muir-Torre syndrome: diagnostic and screening guidelines. Australas J Dermatol 47 (2006) 266-269
87. Arnold A., Payne S., Fisher S., Fricker D., Soloway J., White S.M., et al. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation. Fam Cancer 6 (2007) 317-321
88. Ponti G., Losi L., Di Gregorio C., Roncucci L., Pedroni M., Scarselli A., et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 103 (2005) 1018-1025
89. Finan M.C., and Connolly S.M. Sebaceous gland tumors and systemic disease: a clinicopathologic analysis. Medicine (Baltimore) 63 (1984) 232-242
90. Vasen H.F., Wijnen J.T., Menko F.H., Kleibeuker J.H., Taal B.G., Griffioen G., et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110 (1996) 1020-1027
91. Watson P., and Lynch H.T. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71 (1993) 677-685
92. Sijmons R.H., Kiemeney L.A., Witjes J.A., and Vasen H.F. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol 160 (1998) 466-470
93. Ponti G., and Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 6 (2005) 980-987
94. Akhtar S., Oza K.K., Khan S.A., and Wright J. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 41 (1999) 681-686
95. Demirci H., Nelson C.C., Shields C.L., Eagle Jr. R.C., and Shields J.A. Eyelid sebaceous carcinoma associated with Muir-Torre syndrome in two cases. Ophthal Plast Reconstr Surg 23 (2007) 77-79
96. Honchel R., Halling K.C., Schaid D.J., Pittelkow M., and Thibodeau S.N. Microsatellite instability in Muir-Torre syndrome. Cancer Res 54 (1994) 1159-1163
97. Wolfe III J.T., Yeatts R.P., Wick M.R., Campbell R.J., and Waller R.R. Sebaceous carcinoma of the eyelid. Errors in clinical and pathologic diagnosis. Am J Surg Pathol 8 (1984) 597-606
98. Jakobiec F.A. Sebaceous adenoma of the eyelid and visceral malignancy. Am J Ophthalmol 78 (1974) 952-960
99. Rulon D.B., and Helwig E.B. Cutaneous sebaceous neoplasms. Cancer 33 (1974) 82-102
100. de la Chapelle A. Microsatellite instability. N Engl J Med 349 (2003) 209-210
101. Chung D.C., and Rustgi A.K. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 138 (2003) 560-570
102. Kolodner R.D., Tytell J.D., Schmeits J.L., Kane M.F., Gupta R.D., Weger J., et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 59 (1999) 5068-5074
103. Wu Y., Berends M.J., Mensink R.G., Kempinga C., Sijmons R.H., van Der Zee A.G., et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 65 (1999) 1291-1298
104. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
105. Thibodeau S.N., Bren G., and Schaid D. Microsatellite instability in cancer of the proximal colon. Science 260 (1993) 816-819
106. Ionov Y., Peinado M.A., Malkhosyan S., Shibata D., and Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (1993) 558-561
107. Kruse R., Rütten A., Schweiger N., Jakob E., Mathiak M., Propping P., et al. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol 120 (2003) 858-864
108. Entius M.M., Keller J.J., Drillenburg P., Kuypers K.C., Giardiello F.M., and Offerhaus G.J. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 6 (2000) 1784-1789
109. Cesinaro A.M., Ubiali A., Sighinolfi P., Trentini G.P., Gentili F., and Facchetti F. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am J Dermatopathol 29 (2007) 351-358
110. Chiaravalli A.M., Furlan D., Facco C., Tibiletti M.G., Dionigi A., Casati B., et al. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch 438 (2001) 39-48
111. Overbeek L.I., Ligtenberg M.J., Willems R.W., Hermens R.P., Blokx W.A., Dubois S.V., et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 32 (2008) 1246-1251
112. Mathiak M., Rütten A., Mangold E., Fischer H.P., Ruzicka T., Friedl W., et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol 26 (2002) 338-343
113. Hare H.H., Mahendraker N., Sarwate S., and Tangella K. Muir-Torre syndrome: a rare but important disorder. Cutis 82 (2008) 252-256
114. Mangold E., Pagenstecher C., Leister M., Mathiak M., Rutten A., Friedl W., et al. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet 41 (2004) 567-572
115. Schweizer P., Moisio A.L., Kuismanen S.A., Truninger K., Vierumaki R., Salovaara R., et al. Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. Cancer Res 61 (2001) 2813-2815
116. Chang D.K., Ricciardiello L., Goel A., Chang C.L., and Boland C.R. Steady-state regulation of the human DNA mismatch repair system. J Biol Chem 275 (2000) 29178
117. Marra G., Iaccarino I., Lettieri T., Roscilli G., Delmastro P., and Jiricny J. Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci U S A 95 (1998) 8568-8573
118. de Wind N., Dekker M., Claij N., Jansen L., van Klink Y., Radman M., et al. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet 23 (1999) 359-362
119. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 10 (2008) 293-300
120. de Jong A.E., van Puijenbroek M., Hendriks Y., Tops C., Wijnen J., Ausems M.G., et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10 (2004) 972-980
121. Hampel H., Frankel W.L., Martin E., Arnold M., Khanduja K., Kuebler P., et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352 (2005) 1851-1860
122. Pinol V., Castells A., Andreu M., Castellvi-Bel S., Alenda C., Llor X., et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293 (2005) 1986-1994
123. Vasen H.F.A., Moslein G., Alonso A., Bernstein I., Bertario L., Blanco I., et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44 (2007) 353-362
124. Peltomäki P., and Vasen H. Mutations associated with HNPCC predisposition-update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20 (2004) 269-276
125. Salahshor S., Koelble K., Rubio C., and Lindblom A. Microsatellite Instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Invest 81 (2001) 535-541
126. Niessen R.C., Berends M.J., Wu Y., Sijmons R.H., Hollema H., Ligtenberg M.J., et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut 55 (2006) 1781-1788
127. Southey M.C., Jenkins M.A., Mead L., Whitty J., Trivett M., Tesoriero A.A., et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 23 (2005) 6524-6532
128. Engel C., Forberg J., Holinski-Feder E., Pagenstecher C., Plaschke J., Kloor M., et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 118 (2006) 115-122
129. Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., et al. Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. J Clin Oncol 20 (2002) 1203-1208
130. Barnetson R.A., Tenesa A., Farrington S.M., Nicholl I.D., Cetnarskyj R., Porteous M.E., et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354 (2006) 2751-2763
131. Cunningham J.M., Kim C.Y., Christensen E.R., Tester D.J., Parc Y., Burgart L.J., et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69 (2001) 780-790
132. Debniak T., Kurzawski G., Gorski B., Kladny J., Domagala W., and Lubinski J. Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 36 (2000) 49-54
133. Roncari B., Pedroni M., Maffei S., Di Gregorio C., Ponti G., Scarselli A., et al. Frequency of constitutional MSH6 mutations in a consecutive series of families with clinical suspicion of HNPCC. Clin Genet 72 (2007) 230-237
134. Kane M.F., Loda M., Gaida G.M., Lipman J., Mishra R., Goldman H., et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57 (1997) 808-811
135. Simpkins S.B., Bocker T., Swisher E.M., Mutch D.G., Gersell D.J., Kovatich A.J., et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 8 (1999) 661-666
136. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
137. Domingo E., Laiho P., Ollikainen M., Pinto M., Wang L., French A.J., et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41 (2004) 664-668
138. Domingo E., Espín E., Armengol M., Oliveira C., Pinto M., Duval A., et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 39 (2004) 138-142
139. Deng G., Bell I., Crawley S., Gum J., Terdiman J.P., Allen B.A., et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10 (2004) 191-195
140. Sommerer F., Vieth M., Markwarth A., Rohrich K., Vomschloss S., May A., et al. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 23 (2004) 554-558
141. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., and Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96 (1999) 8681-8686
142. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95 (1998) 6870-6875
143. Wolf B., Gruber S., Henglmueller S., Kappel S., Bergmann M., Wrba F., et al. Efficiency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in Austrian HNPCC patients. Int J Cancer 118 (2006) 1465-1470
144. Salovaara R., Loukola A., Kristo P., Kaariainen H., Ahtola H., Eskelinen M., et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18 (2000) 2193-2200
145. Aaltonen L.A., Salovaara R., Kristo P., Canzian F., Hemminki A., Peltomaki P., et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338 (1998) 1481-1487
146. Vasen H.F., Moslein G., Alonso A., Bernstein I., Bertario L., Blanco I., et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44 (2007) 353-362
147. Wijnen J.T., Vasen H.F., Khan P.M., Zwinderman A.H., van der Klift H., Mulder A., et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 339 (1998) 511-518
148. de Vos tot Nederveen Cappel W.H., Nagengast F.M., Griffioen G., Menko F.H., Taal B.G., Kleibeuker J.H., et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45 (2002) 1588-1594
149. Arrigoni A., Sprujevnik T., Alvisi V., Rossi A., Ricci G., Pennazio M., et al. Clinical identification and long-term surveillance of 22 hereditary non-polyposis colon cancer Italian families. Eur J Gastroenterol Hepatol 17 (2005) 213-219
150. Renkonen-Sinisalo L., Aarnio M., Mecklin J.P., and Jarvinen H.J. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 24 (2000) 137-142
151. Jarvinen H.J., Aarnio M., Mustonen H., Aktan-Collan K., Aaltonen L.A., Peltomaki P., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 (2000) 829-834
152. Jarvinen H.J., Mecklin J.P., and Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108 (1995) 1405-1411
153. Vasen H.F., Taal B.G., Nagengast F.M., Griffioen G., Menko F.H., Kleibeuker J.H., et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 31A (1995) 1145-1148
154. Vasen H.F., den Hartog Jager F.C., Menko F.H., and Nagengast F.M. Screening for hereditary non-polyposis colorectal cancer: a study of 22 kindreds in The Netherlands. Am J Med 86 (1989) 278-281
155. Mecklin J.P., Jarvinen H.J., Aukee S., Elomaa I., and Karjalainen K. Screening for colorectal carcinoma in cancer family syndrome kindreds. Scand J Gastroenterol 22 (1987) 449-453
156. Love R.R., and Morrissey J.F. Colonoscopy in asymptomatic individuals with a family history of colorectal cancer. Arch Intern Med 144 (1984) 2209-2211
157. Dove-Edwin I., Boks D., Goff S., Kenter G.G., Carpenter R., Vasen H.F., et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94 (2002) 1708-1712
158. Syngal S., Weeks J.C., Schrag D., Garber J.E., and Kuntz K.M. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129 (1998) 787-796
159. Lynch H.T., Boland C.R., Gong G., Shaw T.G., Lynch P.M., Fodde R., et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 14 (2006) 390-402
160. Lindor N.M., Petersen G.M., Hadley D.W., Kinney A.Y., Miesfeldt S., Lu K.H., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296 (2006) 1507-1517
161. Schmeler K.M., Lynch H.T., Chen L.M., Munsell M.F., Soliman P.T., Clark M.B., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 (2006) 261-269
162. Umar A., Boland C.R., Terdiman J.P., Syngal S., de la Chapelle A., Ruschoff J., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004) 261-268